1
|
Zwan MD, Villemagne VL, Doré V, Buckley R, Bourgeat P, Veljanoski R, Salvado O, Williams R, Margison L, Rembach A, Macaulay SL, Martins R, Ames D, van der Flier WM, Ellis KA, Scheltens P, Masters CL, Rowe CC. Subjective Memory Complaints in APOEɛ4 Carriers are Associated with High Amyloid-β Burden. J Alzheimers Dis 2016; 49:1115-22. [PMID: 26639956 DOI: 10.3233/jad-150446] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND APOEɛ4 genotype and aging have been identified as risk factors for Alzheimer's disease (AD). In addition, subjective memory complaints (SMC) might be a first clinical expression of the effect of AD pathology on cognitive functioning. OBJECTIVE To assess whether APOEɛ4 genotype, age, SMC, and episodic memory are risk factors for high amyloid-β (Aβ) burden in cognitively normal elderly. METHODS 307 cognitively normal participants (72.7 ± 6.8 years, 53% female, 55% SMC) from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study underwent amyloid PET and APOE genotyping. Logistic regression analyses were performed to determine the association of APOEɛ4 genotype, age, SMC, and episodic memory with Aβ pathology. RESULTS Odds of high Aβ burden were greater at an older age (OR = 3.21; 95% CI = 1.68-6.14), when SMC were present (OR = 1.90; 95% CI = 1.03-3.48), and for APOEɛ4 carriers (OR = 7.49; 95% CI = 3.96-14.15), while episodic memory was not associated with odds of high Aβ burden. Stratified analyses showed that odds of SMC for high Aβ burden were increased in specifically APOEɛ4 carriers (OR = 4.58, 95% CI = 1.83-11.49) and younger participants (OR = 3.73, 95% CI = 1.39-10.01). CONCLUSION Aging, APOEɛ4 genotype, and SMC were associated with high Aβ burden. SMC were especially indicative of high Aβ burden in younger participants and in APOEɛ4 carriers. These findings suggest that selection based on the presence of SMC, APOEɛ4 genotype and age may help identify healthy elderly participants with high Aβ burden eligible for secondary prevention trials.
Collapse
Affiliation(s)
- Marissa D Zwan
- Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.,Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Victor L Villemagne
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia.,The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia
| | - Vincent Doré
- CSIRO Digital Productivity Flagship, The Australian e-Health Research Centre - BioMedIA, Herston, Queensland, Australia
| | - Rachel Buckley
- The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.,Melbourne School of Psychological Sciences, The University of Melbourne, Victoria, Australia
| | - Pierrick Bourgeat
- CSIRO Digital Productivity Flagship, The Australian e-Health Research Centre - BioMedIA, Herston, Queensland, Australia
| | - Robyn Veljanoski
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Olivier Salvado
- CSIRO Digital Productivity Flagship, The Australian e-Health Research Centre - BioMedIA, Herston, Queensland, Australia
| | - Rob Williams
- The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia
| | - Laura Margison
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Alan Rembach
- The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia
| | | | - Ralph Martins
- Centre of Excellence for Alzheimer's Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
| | - David Ames
- National Ageing Research Institute, Parkville, Victoria, Australia.,Department of Psychiatry, The University of Melbourne, Victoria, Australia
| | - Wiesje M van der Flier
- Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.,Department of Epidemiology and Biostatistics, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
| | - Kathryn A Ellis
- The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.,Department of Psychiatry, The University of Melbourne, Victoria, Australia
| | - Philip Scheltens
- Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
| | - Colin L Masters
- The Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia
| | - Christopher C Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| |
Collapse
|
2
|
Rowe CC, Jones G, Doré V, Pejoska S, Margison L, Mulligan RS, Chan JG, Young K, Villemagne VL. Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale. J Nucl Med 2016; 57:1233-7. [PMID: 26912446 DOI: 10.2967/jnumed.115.171595] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2015] [Accepted: 01/29/2016] [Indexed: 11/16/2022] Open
Abstract
UNLABELLED A common quantitative output value for PET measures of β-amyloid (Aβ) binding across tracers and methods would allow better comparison of data across sites and application of universal diagnostic and prognostic values. A method has recently been developed that generates a unit of measurement called the centiloid. We applied this method to 2-[2-(18)F-fluoro-6-(methylamino)-3-pyridinyl]-1-benzofuran-5-ol ((18)F-NAV4694) and (11)C-Pittsburgh compound B ((11)C-PiB) Aβ images to derive the scaling factor required to express tracer binding in centiloids. METHODS Fifty-five participants, including 10 young controls (33 ± 7 y old), underwent both (11)C-PiB and (18)F-NAV4694 imaging no more than 3 mo apart, with the images acquired 50-70 min after tracer injection. The images were spatially normalized and analyzed using the standard centiloid method and regions (cortex and whole-cerebellum reference) downloaded from the Global Alzheimer Association Interactive Network website. RESULTS SUV ratios (SUVRs) showed a strong correlation in tracer binding ((18)F-NAV4694 SUVR = 1.09 × (11)C-PiB SUVR - 0.08, R(2) = 0.99). The equation to convert (18)F-NAV4694 to centiloids [100 × ((18)F-NAV4694 SUVR - 1.028)/1.174] was similar to a published equation for (11)C-PiB [100 × ((11)C-PiB SUVR - 1.009)/1.067]. In the young controls, the variance ratio ((18)F-NAV4694 centiloid SD divided by (11)C-PiB centiloid SD) was 0.85. CONCLUSION The results for both (11)C-PiB and (18)F-NAV4694 can now be expressed in centiloids, an important step that should allow better clinical and research use of Aβ imaging. The standard centiloid method also showed that (18)F-NAV4694 has slightly higher Aβ binding and lower variance than (11)C-PiB, important properties for detecting early Aβ deposition and change over time.
Collapse
Affiliation(s)
- Christopher C Rowe
- Department of Molecular Imaging, Austin Health, Melbourne, Australia Department of Medicine, University of Melbourne, Melbourne, Australia
| | - Gareth Jones
- Department of Molecular Imaging, Austin Health, Melbourne, Australia
| | - Vincent Doré
- Department of Molecular Imaging, Austin Health, Melbourne, Australia CSIRO Health and Biosecurity, Brisbane, Australia; and
| | - Svetlana Pejoska
- Department of Molecular Imaging, Austin Health, Melbourne, Australia
| | - Laura Margison
- Department of Molecular Imaging, Austin Health, Melbourne, Australia
| | - Rachel S Mulligan
- Department of Molecular Imaging, Austin Health, Melbourne, Australia
| | - J Gordon Chan
- Department of Molecular Imaging, Austin Health, Melbourne, Australia
| | - Kenneth Young
- Department of Molecular Imaging, Austin Health, Melbourne, Australia
| | - Victor L Villemagne
- Department of Molecular Imaging, Austin Health, Melbourne, Australia Department of Medicine, University of Melbourne, Melbourne, Australia Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| |
Collapse
|